Mortality in DATATOP: A Multicenter trial in early Parkinson's disease
- 1 March 1998
- journal article
- clinical trial
- Published by Wiley in Annals of Neurology
- Vol. 43 (3), 318-325
- https://doi.org/10.1002/ana.410430309
Abstract
Deprenyl (selegiline) delays the need for levodopa therapy in patients with early Parkinson's disease, but the value of long‐term treatment with this type B monoamine oxidase inhibitor remains unsettled. We examined mortality among the 800 patients with early Parkinson's disease who were not requiring levodopa and who were randomly assigned in the DATATOP trial to receive deprenyl, tocopherol, combined treatments, or placebo. Ascertainment of the vital status of subjects in this double‐blinded trial was performed prospectively after the initial randomization, during open‐label de‐prenyl, and after a second independent randomization to continue active deprenyl or swithch to matching placebo. The study was conducted at 28 academic medical centers in the United States and Canada. After an average of 8.2 years of observation, the overall death rate of our subjects was 17.1% (137 of 800) or 2.1% per year. The mortality rate was unaffected by deprenyl, tocopherol, or combined treatment assignments and was about that expected for an age‐ and gender‐matched US population without Parkinson's disease. Neither deprenyl, tocopherol, nor their combined treatments affected the duration of life in our early Parkinson's disease patients. The deprenyl‐related delay in disability that we reported previously was not associated with a deprenyl‐related reduction in mortality.Keywords
This publication has 18 references indexed in Scilit:
- Presalvage prostate‐specific antigen (PSA) and PSA doubling time as predictors of biochemical failure of salvage cryotherapy in patients with locally recurrent prostate cancer after radiotherapyCancer, 2006
- Further evidence of increased risk of mortality of Parkinson's disease.Journal of Neurology, Neurosurgery & Psychiatry, 1996
- Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopaAnnals of Neurology, 1996
- Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. Parkinson's Disease Research Group in the United Kingdom.BMJ, 1993
- Effects of Tocopherol and Deprenyl on the Progression of Disability in Early Parkinson's DiseaseNew England Journal of Medicine, 1993
- The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomaticAnnals of Neurology, 1992
- Parkinson's disease in Aberdeen: survival after 3.5 yearsActa Neurologica Scandinavica, 1990
- Effect of Deprenyl on the Progression of Disability in Early Parkinson's DiseaseNew England Journal of Medicine, 1989
- The analysis of event history data: A review of progress and outstanding problemsStatistics in Medicine, 1988
- Increased life expectancy resulting from addition of l-deprenyl to Madopar® treatment in Parkinson's disease: A longterm studyJournal of Neural Transmission, 1985